Abstract:fi2AR is an important drug target protein involving many diseases. Biased drugs induce specific signaling and provide additional clinical utility to optimize fi2AR-based therapies. However, the biased signaling mechanism has not been elucidated. Motivated by the issue, we chose four agonists with divergent bias (balanced agonist, G-protein-biased agonist, and fi-arrestin-biased agonists) and utilized Gaussian accelerated molecular dynamics simulation coupled with a dynamic network to probe the molecular mechanisms of distinct biased activation induced by the structural differences between the four agonists. Our simulations reveal that the G-protein-biased agonist induces an open conformation with the outward shifts of TM6 and TM7 for the intracellular domain, which will be beneficial to couple G protein. In contrast, the fi- arrestin-biased agonists regulate an occluded conformation with a slightly outward movement of TM6 and an inward shift of TM7, which should favor fi-arrestin signaling. The balanced agonist does not induce an observable outward shift for TM6 but, along with a slight tilt for TM7, leads to an inactive-like conformation. In addition, our results reveal the first time that ICL3 presents specific conformations with different agonists. The G-protein-biased agonist drives ICL3 to open so that the G protein-binding pocket can be available, while the fi-arrestin-biased agonists induce ICL3 to form a closed conformation with a stable local a-helix. MM/PBSA analysis further reveals that the hydroxyl groups in the resorcinol of the G-protein-biased agonist form strong interactions with Y5.38 and S5.42, thus preventing tilting of the TM5 extracellular end. The catechol of the balanced agonist and the fi-arrestin-biased ones induces the rearrangement of two hydrophobic residues F6.52 and W6.48. However, different from the balanced agonist, the ethyl substituent of fi-arrestin-biased agonists forms additional hydrophobic interactions with W6.48 and F6.51 after the rearrangement, which should contribute to the fi-arrestin bias. The shortest pathway analysis further reveals that the three residues Y7.43, N7.45, and N7.49 are crucial for allosterically regulating G-protein-biased signaling, while the two residues W6.48 and F6.44 make an important contribution to regulate fi-arrestin-biased signaling. For the balanced agonist NE, the allosteric regulation pathway simultaneously involves the residue associated with G-protein-biased signaling like S5.46 and the residues related to fi-arrestin-biased signaling like W6.48 and F6.44, thus producing unbiased signaling. The observations could advance our understanding of the biased activation mechanism on class A GPCRs and provide a useful guideline for the design of biased drugs.

Biased agonism of carvedilol in the beta1-adrenergic receptor is governed by conformational exclusion

Gα i is required for carvedilol-induced β 1 adrenergic receptor β-arrestin biased signaling

G Alpha(I) Is Required For Carvedilol-Induced Beta(1) Adrenergic Receptor Beta-Arrestin Biased Signaling

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Distinct Conformations of GPCR–β-arrestin Complexes Mediate Desensitization, Signaling, and Endocytosis

Molecular mechanism of biased signaling in a prototypical G protein–coupled receptor

Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR

Molecular Mechanisms of Diverse Activation Stimulated by Different Biased Agonists for the 2-Adrenergic Receptor

Molecular basis of β-arrestin coupling to formoterol-bound β1-adrenoceptor

A New Series of Gs‐ and Β‐arrestin‐biased Β2‐adrenoceptor Agonists

Flavors of GPCR signaling bias

Β-Arrestin–biased Allosteric Modulator Potentiates Carvedilol-Stimulated Β Adrenergic Receptor Cardioprotection

Biased Ligands Differentially Shape the Conformation of the Extracellular Loop Region in 5-HT2B Receptors

G protein–coupled receptor endocytosis generates spatiotemporal bias in β-arrestin signaling

Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics

Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility

β-blockers augment L-type Ca2+ channel activity by target-selective spatially restricted β2AR-cAMP-PKA signaling in neurons

Discovery of Β-Arrestin-biased Β2-Adrenoceptor Agonists from 2-Amino-2-phenylethanol Derivatives

Biased Signaling Agonists Promote Distinct Phosphorylation and Conformational States of the Dopamine D3 Receptor

Heterotrimeric Gq proteins act as a switch for GRK5/6 selectivity underlying β-arrestin transducer bias

Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms